Advertisement

Advances in Therapy

, Volume 36, Issue 9, pp 2296–2309 | Cite as

Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator

  • Xin Zhao
  • Hongyi Wu
  • Huajie Xu
  • Li Shen
  • Bing FanEmail author
  • Junbo GeEmail author
Original Research
  • 34 Downloads

Abstract

Introduction

High on-treatment residual platelet reactivity (HRPR) was associated with greater atherosclerosis burden. We examined whether intrinsic hypercoagulability (IHC) could be attributed to that association in patients treated by drug-eluting stents.

Methods

This retrospective observation enrolled a total of 891 coronary artery disease (CAD) subjects. Platelet and coagulant reactivity was measured by thrombelastography. At least 24 h after a 300-mg dose of clopidogrel, adenosine diphosphate (ADP)-induced maximum amplitude of clot strength (MAadp) > 47 mm represented HRPR. Thrombin-induced platelet–fibrin clot strength (MAthrombin) and blood fibrinogen surrogated intrinsic coagulability. Using mediation analysis to evaluate the effect of IHC on the relationship between the number of narrowed coronaries and HRPR on clopidogrel.

Results

More HRPR on clopidogrel and higher intrinsic coagulability were observed in more severe coronary atherosclerosis, especially in the three-vessel disease. After adjustment for confounding factors, the number of narrowed coronaries (ORadj = 1.343, 95% CI 1.063–1.695, p = 0.013), MAthrombin (ORadj = 1.106, 95% CI 1.058–1.157, p < 0.001), and fibrinogen (ORadj = 1.003, 95% CI 1.001–1.005, p = 0.012) were all independent positive predictors for HRPR. MAthrombin and fibrinogen were meaningful mediators for the significant positive association of the number of narrowed vessels and HRPR on clopidogrel, which were enhanced by around 30% and 43%, respectively, for this effect.

Conclusions

This is the first study to demonstrate that the positive correlation between the number of stenotic coronaries and HRPR on clopidogrel may be partly attributed to IHC, which may enhance the risk stratification, guide more precise coagulation in multi-vessel disease after drug-eluting stents, and therefore deserve further study.

Keywords

Antiplatelet agents Clot strength Fibrinogen Intrinsic coagulability Three-vessel disease 

Notes

Acknowledgements

We thank the participants in the study.

Funding

This work and the Rapid Service Fee were supported by the National Natural Science Foundation of China (81300152; 81521001) and the National Key Research and Development Program of China (2016YFC1301303; 2016YFC1301302).

Authorship

All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authorship Contributions

Xin Zhao and Hongyi Wu contributed equally to this work.

Disclosures

Xin Zhao, Hongyi Wu, Huajie Xu, Li Shen, Bing Fan and Junbo Ge have nothing to disclose.

Compliance with Ethics Guidelines

The protocol complied with the Declaration of Helsinki, and was approved by the hospital ethics review board (No. 2011-152, Zhongshan Hospital, Fudan University, Shanghai, China). As the registry involved de-identified data, informed consent was not required.

Data Availability

The datasets generated during and analyzed during the current study are not publicly available due to the regulations of our hospital, but are available from the corresponding author on reasonable request.

Supplementary material

12325_2019_1032_MOESM1_ESM.docx (111 kb)
Supplementary material 1 (DOCX 111 kb)

References

  1. 1.
    Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2015;10(9):1024–94.CrossRefGoogle Scholar
  2. 2.
    Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961–72.CrossRefGoogle Scholar
  3. 3.
    Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629–38.CrossRefGoogle Scholar
  4. 4.
    Geisler T, Zurn C, Simonenko R, et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J. 2010;31(1):59–66.CrossRefGoogle Scholar
  5. 5.
    Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382(9892):614–23.CrossRefGoogle Scholar
  6. 6.
    Mangiacapra F, de Bruyne B, Muller O, et al. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2010;3(1):35–40.CrossRefGoogle Scholar
  7. 7.
    Chirumamilla AP, Maehara A, Mintz GS, et al. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging. 2012;5(5):540–9.CrossRefGoogle Scholar
  8. 8.
    Redfors B, Ben-Yehuda O, Lin SH, et al. Quantifying ischemic risk after percutaneous coronary intervention attributable to high platelet reactivity on clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study). Am J Cardiol. 2017;120(6):917–23.CrossRefGoogle Scholar
  9. 9.
    Gurbel PA, Bliden KP, Navickas IA, et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J. 2010;160(2):346–54.CrossRefGoogle Scholar
  10. 10.
    Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol. 2005;46(10):1820–6.CrossRefGoogle Scholar
  11. 11.
    Jeong YH, Bliden KP, Shuldiner AR, et al. Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. Thromb Haemost. 2014;111(4):713–24.CrossRefGoogle Scholar
  12. 12.
    Gremmel T, Kopp CW, Seidinger D, et al. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients. Eur J Clin Invest. 2013;43(7):689–97.CrossRefGoogle Scholar
  13. 13.
    Mahmud E, Cavendish JJ, Tsimikas S, et al. Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention. J Am Coll Cardiol. 2007;49(22):2163–71.CrossRefGoogle Scholar
  14. 14.
    Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41(4 Suppl S):62S–9S.CrossRefGoogle Scholar
  15. 15.
    Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.CrossRefGoogle Scholar
  16. 16.
    Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799–808.CrossRefGoogle Scholar
  17. 17.
    Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319–30.CrossRefGoogle Scholar
  18. 18.
    Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;64(18):1929–49.CrossRefGoogle Scholar
  19. 19.
    Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.CrossRefGoogle Scholar
  20. 20.
    IBANEZ B, JAMES S, AGEWALL S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2017.Google Scholar
  21. 21.
    Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261–73.CrossRefGoogle Scholar
  22. 22.
    Hayes AF, Rockwood NJ. Regression-based statistical mediation and moderation analysis in clinical research: observations, recommendations, and implementation. Behav Res Ther. 2017;98:39–57.CrossRefGoogle Scholar
  23. 23.
    Zhang Y, Zhu CG, Guo YL, et al. Fibrinogen and the severity of coronary atherosclerosis among adults with and without statin treatment: lipid as a mediator. Heart Lung Circ. 2016;25(6):558–67.CrossRefGoogle Scholar
  24. 24.
    Albert JM. Mediation analysis via potential outcomes models. Stat Med. 2008;27(8):1282–304.CrossRefGoogle Scholar
  25. 25.
    Tantry US, Bliden KP, Suarez TA, et al. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic Risk Progression (TRIP) study. Platelets. 2010;21(5):360–7.CrossRefGoogle Scholar
  26. 26.
    Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol. 2011;8(9):502–12.CrossRefGoogle Scholar
  27. 27.
    Escaned J, Collet C, Ryan N, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. Eur Heart J. 2017;38(42):3124–34.CrossRefGoogle Scholar
  28. 28.
    Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013;381(9867):639–50.CrossRefGoogle Scholar
  29. 29.
    Rivard GE, Brummel-Ziedins KE, Mann KG, et al. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost. 2005;3(9):2039–43.CrossRefGoogle Scholar
  30. 30.
    Swiger KJ, Yousuf O, Bliden KP, et al. Cigarette smoking and clopidogrel interaction. Curr Cardiol Rep. 2013;15(5):361.CrossRefGoogle Scholar
  31. 31.
    Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919–33.CrossRefGoogle Scholar
  32. 32.
    Stuckey TD, Kirtane AJ, Brodie BR, et al. Impact of aspirin and clopidogrel hyporesponsiveness in patients treated with drug-eluting stents: 2-year results of a prospective, multicenter registry study. JACC Cardiovasc Interv. 2017;10(16):1607–17.CrossRefGoogle Scholar
  33. 33.
    Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159–64.CrossRefGoogle Scholar
  34. 34.
    Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100–9.CrossRefGoogle Scholar
  35. 35.
    Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097–105.CrossRefGoogle Scholar
  36. 36.
    Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.CrossRefGoogle Scholar
  37. 37.
    Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.CrossRefGoogle Scholar
  38. 38.
    Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017.Google Scholar
  39. 39.
    Gurbel PA, Tantry US. GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. Lancet. 2017;389(10081):1773–5.CrossRefGoogle Scholar
  40. 40.
    Esmon CT. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost. 2014;111(4):625–33.CrossRefGoogle Scholar
  41. 41.
    Wu H, Qian J, Wang Q, et al. Thrombin induced platelet–fibrin clot strength measured by thrombelastography is a novel marker of platelet activation in acute myocardial infarction. Int J Cardiol. 2014;172(1):e24–5.CrossRefGoogle Scholar
  42. 42.
    Woodward M, Lowe GD, Francis LM, et al. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost. 2004;2(11):1934–40.CrossRefGoogle Scholar
  43. 43.
    Ndrepepa G, Braun S, King L, et al. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2013;111(6):804–10.CrossRefGoogle Scholar
  44. 44.
    Zhang Y, Zhu C, Guo Y, et al. Higher fibrinogen level is independently linked with the presence and severity of new-onset coronary atherosclerosis among han Chinese population. PLoS ONE. 2014;9(11):e113460.CrossRefGoogle Scholar
  45. 45.
    Ang L, Thani KB, Ilapakurti M, et al. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. J Am Coll Cardiol. 2013;61(1):23–34.CrossRefGoogle Scholar
  46. 46.
    Lv HC, Wu HY, Yin JS, et al. Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease. Oncotarget. 2017;8(38):64217–23.CrossRefGoogle Scholar
  47. 47.
    Cheung MWL. Comparison of approaches to constructing confidence intervals for mediating effects using structural equation models. Struct Equ Model. 2007;14:227–46.CrossRefGoogle Scholar
  48. 48.
    Kaptoge S, di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–20.CrossRefGoogle Scholar
  49. 49.
    Marianne TS, Kim O, Søren PJ, et al. Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br J Haematol. 2010;149:273–9.CrossRefGoogle Scholar
  50. 50.
    Peverill RE, Teede HJ, Malan E, et al. Relationship of waist and hip circumference with coagulation and fibrinolysis in postmenopausal women. Clin Sci. 2007;113(9):383–91.CrossRefGoogle Scholar
  51. 51.
    Campello E, Spiezia L, Zabeo E, et al. Hypercoagulability detected by whole blood thromboelastometry (ROTEM®) and impedance aggregometry (MULTIPLATE®) in obese patients. Thromb Res. 2015;135:548–53.CrossRefGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan HospitalFudan UniversityShanghaiChina
  2. 2.Department of Cardiology, Jinshan HospitalFudan UniversityShanghaiChina

Personalised recommendations